CCL17 and melanoma: Their results demonstrated that CCL17 (but not CCL22) was sufficient to enhance melanoma cell invasiveness in the brain, and blocking CCR4 in vivo using a CCR4-antagonist small molecule reduced the tumorigenicity and micrometastasis formation of melanoma cells.